ModernaMRNA
MRNA
About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Employees: 5,800
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
14% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]
4.92% more ownership
Funds ownership: 66.92% [Q3] → 71.84% (+4.92%) [Q4]
6% less funds holding
Funds holding: 770 [Q3] → 725 (-45) [Q4]
10% less repeat investments, than reductions
Existing positions increased: 225 | Existing positions reduced: 250
15% less first-time investments, than exits
New positions opened: 140 | Existing positions closed: 165
20% less call options, than puts
Call options by funds: $929M | Put options by funds: $1.16B
33% less capital invested
Capital invested by funds: $17.2B [Q3] → $11.5B (-$5.67B) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
30%
upside
Avg. target
$45
81%
upside
High target
$78
216%
upside
9 analyst ratings
1 positive
11%
6 neutral
67%
2 negative
22%
Morgan Stanley Matthew Harrison 38% 1-year accuracy 9 / 24 met price target | 30%upside $32 | Equal-Weight Maintained | 9 Apr 2025 |
JP Morgan Jessica Fye 53% 1-year accuracy 19 / 36 met price target | 34%upside $33 | Underweight Maintained | 21 Mar 2025 |
Citigroup Geoff Meacham 36% 1-year accuracy 12 / 33 met price target | 62%upside $40 | Neutral Initiated | 13 Mar 2025 |
UBS Eliana Merle 16% 1-year accuracy 3 / 19 met price target | 216%upside $78 | Buy Maintained | 19 Feb 2025 |
RBC Capital Luca Issi 7% 1-year accuracy 4 / 55 met price target | 62%upside $40 | Sector Perform Reiterated | 18 Feb 2025 |
Financial journalist opinion
Based on 23 articles about MRNA published over the past 30 days
Neutral
Zacks Investment Research
2 days ago
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close.
Positive
Zacks Investment Research
6 days ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Neutral
Investors Business Daily
1 week ago
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.
Neutral
Accesswire
1 week ago
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update.
Negative
The Motley Fool
1 week ago
Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022
The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%.
Neutral
Accesswire
1 week ago
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025. Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases.
Positive
The Motley Fool
2 weeks ago
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (PFE 0.77%) and Moderna (MRNA 2.21%). These two vaccine makers made small fortunes thanks to their work in this space.
Positive
The Motley Fool
2 weeks ago
FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?
Moderna (MRNA 2.21%) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer.
Neutral
CNBC
2 weeks ago
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Negative
Zacks Investment Research
2 weeks ago
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
Charts implemented using Lightweight Charts™